Press release
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not metLosmapimod showed statistically
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not metLosmapimod showed statistically significant* (p","length":394,"tagName":"div"}]